Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vx-001 in non-small cell lung cancer (Phase IIb)
2011-005968-24Phase 2Terminated
- Sponsor
- Vaxon Biotech
- Start
- Feb 2012
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Vx-001 with Placebo (2 arms). Primary endpoint: 12-month survival rate. Started Feb 2012; status: terminated.
02
Drugs
vx-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-005968-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005968-24.